6533b82efe1ef96bd1293075
RESEARCH PRODUCT
European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?
Giovanni GalatiGennaro Gadaleta-caldarolaGiuseppe CabibboGiuseppe LombardiGiancarlo MazzaRodolfo Saccosubject
SorafenibCancer Researchmedicine.medical_specialtygeographyCirrhosisSummitgeography.geographical_feature_categorybusiness.industryCost effectivenessComplex diseaseGeneral Medicinemedicine.diseaseGastroenterologyNatural historyOncologyInternal medicineHepatocellular carcinomaFamily medicineMedicinebusinessmedicine.drugdescription
, the European Association for the Study of the Liver (EASL) organized the 2014 EASL HCC Summit in Geneva, Switzerland from 13 to 16 February 2014. A number of interesting issues on the management of hepatocellular carci-noma (HCC) have been addressed during this meeting. However, our feeling is that only few answers have been given to those questions, mainly because of the still poor knowledge of the molecular basis and the natural history of HCC.HCC is a complex disease, associated in the wide majority of cases with under -lying cirrhosis. In addition, HCC pre-sents with high heterogeneity
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-08-01 | Future Oncology |